Context: Hypoglycemia is common among hospitalized patients with and without diabetes mellitus.
S
pontaneous and insulin-related hypoglycemia is common among hospitalized patients with and without diabetes mellitus (DM) (1, 2) . The definition of hypoglycemia in hospitalized patients is poorly defined; thus, the true prevalence of hypoglycemia during hospitalization is variable. The American Diabetes Association (ADA) defines hypoglycemia as blood glucose levels ,70 mg/dL (3.9 mmol/L), and severe hypoglycemia as hypoglycemia requiring assistance from another person, characterized by cognitive impairment that may be recognized or unrecognized and can progress to loss of consciousness, seizure, coma, or death, and is reversed by administration of rapid-acting glucose. As for hospitalized patients, hypoglycemia is similarly defined as any blood glucose level ,70 mg/dL (3.9 mmol/L), and severe hypoglycemia as a blood glucose level ,40 mg/dL (2.2 mmol/L) (3) . The prevalence of hypoglycemia based on a blood glucose value of ,70 mg/dL (3.9 mmol/L) varies between 3.5% and 11% among noncritically ill patients (1, 2, 4, 5) .
The American Diabetes Association recommends initiating insulin therapy for treatment of persistent hyperglycemia starting at a threshold of 180 mg/dL (10 mmol/L) and higher, aiming at a target glucose range of 140 to 180 mg/dL (7.8 to 10 mmol/L) for critically and noncritically ill patients (3) . However, in-hospital insulin therapy is associated with an increased risk of hypoglycemia (6) . Inpatient hypoglycemia is frequently asymptomatic; this is due to hypoglycemia unawareness or altered consciousness associated with acute illness or drug therapy (4) . Hypoglycemia is associated with several complications, including neurologic and ischemic events, longer hospital stay, and an increased mortality risk (1, 2, 7-13). Curkendall et al. (9) reported that patients with any blood glucose value of ,70 mg/dL (3.9 mmol/L) had 7% higher odds of in-hospital mortality compared with patients without hypoglycemia.
In this study, the association between spontaneous and insulin-related hypoglycemia, including severe hypoglycemia and all-cause mortality, was evaluated among a large cohort of hospitalized patients.
Methods
The study was conducted in a large, 1300-bed, universityaffiliated tertiary medical center. Most of the admissions to the 10 medical wards are through the emergency department. All patient data are recorded in electronic medical charts, which are based on the same database platform used in the community primary care facilities. Deaths are entered into the hospital's mortality database, which is updated according to the population registry of the Ministry of the Interior.
For the current study, historical, prospectively collected observational data were extracted from the medical records of all patients who were admitted for any cause to the hospital's medical wards between 1 January 2011 and 31 December 2013. In patients with multiple admissions, only the first admission was analyzed. Mortality data were obtained up to 1 June 2015. Self-reported data regarding alcohol use, smoking, and body mass index, as well as comorbidities, were also collected from the database.
DM was defined as a previous diagnosis of DM in the medical records or use of any oral hypoglycemic agent, glucagon-like peptide 1 agonist, or insulin at the time of admission.
Blood glucose values were based on point-of-care bedside measurements or serum glucose levels in venous samples. Hypoglycemia was defined as at least 1 blood glucose measurement of ,70 mg/dL (3.9 mmol/L); moderate hypoglycemia was defined as blood glucose values between 40 and 70 mg/dL (2.2 to 3.9 mmol/L) during hospitalization; and severe hypoglycemia was defined as blood glucose ,40 mg/dL (2.2 mmol/L). Hospitalized patients without hypoglycemia (blood glucose .70 mg/dL (3.9 mmol/L) served as control groups, and were classified into 2 groups: noninsulin-treated controls (NITC) and insulin-treated controls (ITC). When hypoglycemia occurred during receipt of insulin therapy, the hypoglycemia was assumed to be insulin related (IH), and when no insulin was used, the hypoglycemia was defined as noninsulin related (NIH). This same rule applied to severe hypoglycemia, which was classified as insulin-related severe hypoglycemia (ISH) and noninsulin-related severe hypoglycemia (NISH). Patients taking sulphonylureas and glinides at admission were excluded, as well as patients with no blood glucose measurement during the admission.
The primary outcome was risk of all-cause mortality at the end of follow-up. The study was approved by the Rabin Medical Center Institutional Review Board.
Statistical analysis
The statistical analysis was generated using SAS software, version 9.4 (SAS Institute, Cary, NC). Analysis of variance with Tukey's correction for multiple comparisons was used to compare continuous variables between groups, and logistic regression with Tukey's correction for multiple comparisons was used for dichotomous variables. Median and mean survival times were assessed with Kaplan-Meier survival analysis. The Cox proportional hazards model was used to assess overall survival adjusted for age, sex, smoking, alcohol, DM, hypertension, malignancy, ischemic heart disease, congestive heart failure, cerebrovascular disease, and chronic renal failure. Two-sided P values ,0.05 were considered statistically significant. We had complete data for all of the study variables, other than alcohol and smoking. No imputation for missing data was performed because missing at random cannot be assumed.
Results

Study cohort
There were 73,796 admissions to the 10 medical wards during the study period. After exclusion of repeat admissions, patients with missing glucose levels, and patients treated with sulfonylurea or glinides, the final study cohort consisted of 33,675 patients (Fig. 1 ). Of these, 17,274 (51%) were male, and the median age was 70 years (range, 18 to 108 years) at admission. According to the medical records, 23,565 (70%) did not have preexisting DM, and 10,110 (30%) had DM. A total of 2893 patients (29%) with DM were treated with insulin prior to admission. Median in-hospital glucose levels were 105 mg/dL (5.8 mmol/L) in patients without DM, and 154 mg/dL (8.6 mmol/L) in patients with DM.
All patients included in the study had at least 1 blood glucose measurement during the admission. As shown in Table 1 , the median number of blood glucose measurements was 3 in the NITC group and 12 in the ITC group. The number of blood glucose measurements was higher for patients receiving insulin treatment compared with noninsulintreated patients. In all 3 groups of patients who received insulin treatment during admission, the number of blood glucose measurements was higher for patients without DM compared with patients with DM. The opposite was true in patients without insulin treatments during the admission.
A total of 2947 patients (9%) had at least 1 blood glucose value of ,70 mg/dL (3.9 mmol/L), including 2605 patients with blood glucose levels of 40 to 70 mg/dL doi: 10.1210/jc. press.endocrine.org/journal/jcem(2.2 to 3.9 mmol/L), indicating moderate hypoglycemia, and 342 patients with blood glucose values of ,40 mg/dL (2.2 mmol/L), indicating severe hypoglycemia. A total of 4727 patients (14%) were treated with insulin during the hospitalization, most of them with preexisting DM (4076 patients; 86%). The patients were divided into 6 groups: (1) NITC (n = 27,213); (2) ITC (n = 3515); (3) NIH (n = 1594); (4) IH (n = 1011); (5) NISH (n = 141); and (6) ISH (n = 201); more patient details are provided in Fig. 1 and Table 1 .
Rates of hypertension, ischemic heart disease, congestive heart failure, cerebrovascular disease, and chronic renal failure were considerably higher in the group of insulin-treated patients compared with noninsulin-treated patients. The characteristics of the patients by group are shown in Table 1 .
Almost half of the patients with hypoglycemia during hospitalization did not have preexisting DM (1452 of 2947 patients; 49%). However, most of the patients with severe hypoglycemia had preexisting DM (236 of 342 patients; 69%). Most of the patients with moderate hypoglycemia were not treated with insulin during the hospitalization (1594 of 2605 patients; 61%), but most of those with severe hypoglycemia received insulin treatment during the hospitalization (201 of 342; 59%).
Median length of hospitalization was longer in patients with insulin-related hypoglycemia (7 days with moderate hypoglycemia and 9 days with severe hypoglycemia), compared with patients without hypoglycemia (3 and 4 days in noninsulin-and insulin-treated patients, respectively; P , 0.001) and compared with patients with noninsulin-related hypoglycemia (5 days; P , 0.001) and severe hypoglycemia (5 days; P = nonsignificant [NS]).
Mortality
Complete follow-up data at 12 months were available for all patients; the first patient was censored after 1.4 years. Median follow-up time was 1022 days.
Overall in-hospital mortality was 6.3% (2105 of 33,675). Rates by group were as follows: NITC, 4 The median survival time after discharge was significantly shorter in patients with severe hypoglycemia compared with patients with moderate hypoglycemia: NIH, 1048 days (range, 812 to 1266 days); IH, 734 days (range, 588 to 973 days); ISH, 97 days (range, 45 to 288 days); NISH, 35 days (range, 1 to 156 days). Accordingly, the major increase in mortality was evident in the first year after discharge; 1-year mortality rates were 40% and 41% for NIH and IH, respectively, compared with 62% and 57% for NISH and ISH, respectively.
Compared with the NITC group, unadjusted hazard ratios (95% confidence intervals [CIs] ) for mortality at the end of follow-up were as follows: ITC, 1.7 (1.6 to 1.8; P , 0.001); NIH, 2.2 (2.0 to 2.4; P , 0.001); IH, 2.5 (2.2 to 2.7; P , 0.001); NISH, 4.2 (3.5 to 5.2; P , 0.001); and ISH, 3.8 (3.2 to 4.5; P , 0.001). After adjustment for age, sex, smoking, alcohol, DM, hypertension, malignancy, ischemic heart disease, congestive heart failure, cerebrovascular disease, and chronic renal failure, respective hazard ratios were 1.8 (1.7 to 2.0; P , 0.001); 2.1 (1.9 to 2.2; P , 0.001); 2.4 (2.1 to 2.6; P , 0.001); 3.2 (2.6 to 3.8; P , 0.001), and 3.6 (3.1 to 4.3; P , 0.001).
Compared with the ITC group, unadjusted hazard ratios (95% CIs) for mortality at the end of follow-up were as follows: NIH, 1.3 (1.2 to 1.4; P , 0.001); IH, 1.4 (1.3 to 1.6; P , 0.001); NISH, 2.5 (2.0 to 3.0; P , 0.001); and ISH, 2.2 (1.9 to 2.7; P , 0.001). After adjustment, respective hazard ratios were 1.1 (1.1 to 1.2; P , 0.01); 1.3 (1.2 to 1.4; P , 0.001); 1.7 (1.4 to 2.1; P , 0.001); and 2.0 (1.7 to 2.4; P , 0.001). Compared with moderate hypoglycemia, unadjusted and adjusted hazard ratios (95% CIs) for mortality with severe hypoglycemia were 1.6 (1.3 to 1.9; P , 0.001) and 1.5 (1.3 to 1.9; P , 0.001) in patients with insulin-associated hypoglycemia, and 1.9 (1.6 to 2.4; P , 0.001) and 1.5 (1.2 to 1.9; P , 0.001) in patients with noninsulin-related hypoglycemia. The KaplanMeier curves depict better survival with noninsulin-related moderate hypoglycemia compared with insulin-related press.endocrine.org/journal/jcemmoderate hypoglycemia. However, in patients with severe hypoglycemia, survival was better initially with insulin-related hypoglycemia, but with longer followup, the survival curves converged (Fig. 3) .
Separate analysis of patients with DM and patients without DM
In patients without DM, compared with the NITC group, unadjusted hazard ratios (95% CIs) for mortality at the end of follow-up were 2.3 (2.1 to 2.5; P , 0.001) with NIH and 5.2 (4.0 to 6.7; P , 0.001) with NISH. The respective adjusted hazard ratios were 2.3 (2.2 to 2.5; P , 0.001) and 3.9 (2.9 to 5.2; P , 0.001). In patients with DM, compared with NITC, unadjusted hazard ratios (95% CI) were 1.9 (1.6 to 2.2; P , 0.001) with NIH and 3.0 (2.2 to 4.1; P , 0.001) with NISH. The respective adjusted hazard ratios were 1.6 (1.4 to 1.9; P , 0.001) and 2.7 (2.0 to 3.8; P , 0.001).
During admission, a total of 4727 patients were treated with insulin, and 28,948 were not treated with insulin. Mortality rates at the end of follow-up were 29.5% in noninsulin-treated patients compared with 46.6% in insulin-treated patients. When analyzed separately, in patients without DM, mortality rates were 28.5% in noninsulin-treated patients (6544 of 22,914 patients) and 59.8% in insulin-treated patients (389 of 651 patients). In patients with DM, the respective mortality rates were 33% (1992 of 6034 patients) and 44.6% (1818 of 4076 patients).
Admission diagnosis
Admission diagnoses were available for 2643 of 2947 (90%) patients with hypoglycemia. The most common diagnoses on admission in the entire cohort were infectious diseases (845 of 2947 patients; 29%), diseases of the circulatory system (432 of 2947 patients; 15%), and diseases of the digestive system (223 of 2947 patients; 8%). Infectious diseases and diseases of the circulatory system were also the most common admission diagnoses in both groups of patients with hypoglycemia not related The association between group and in-hospital mortality was assessed by logistic regression. The overall significance of group was P , 0.001. The pairwise significance, using Tukey's correction for multiple comparisons, was statistically significant for all comparisons (P , 0.05), other than the comparison of ITC with IH (P = 0.59) and the comparison of IH with NIH (P = 0.97). The 30-day, 1-, 2-, and 3-year survival were estimated from the Kaplan-Meier model depicted in Fig. 3 . The significance of difference between groups was stated previously for this model.
to insulin (486 of 1505 patients; 32%; and 220 of 1505 patients; 15%), and patients with insulin-related hypoglycemia (359 of 1138 patients; 32%; and 212 of 1138 patients; 19%; Table 2 ). The cause of admission did not significantly influence the association between hypoglycemia and mortality.
In patients admitted for infectious diseases and diseases of the circulatory system, hazard ratios (95% CIs) for mortality in patients with noninsulin-related hypoglycemia compared with insulin-related hypoglycemia were 0.8 (0.7 to 1.1; P = NS) and 0.7 (0.5 to 1.1; P = NS), respectively.
Discussion
This study indicated increased in-patient and postadmission mortality risk in hospitalized patients with blood glucose levels of ,70 mg/dL (3.9 mmol/L), with and without insulin therapy, compared with hospitalized patients without hypoglycemia. In patients with moderate hypoglycemia, the mortality risk was higher in patients with insulin-related hypoglycemia compared with those with noninsulin-related hypoglycemia, but in those with severe hypoglycemia, mortality was increased irrespective of insulin use. Mortality in patients with severe hypoglycemia was most evident in the first months after discharge, with median time to death of approximately 3 months with insulin-related severe hypoglycemia and 1 month with noninsulin-related severe hypoglycemia. Analyzing the results according to admission diagnoses did not prove a significant interaction between admission diagnoses and study groups. Analyzing the data according to DM status indicated moderate hypoglycemia was associated with a twofold increase in mortality compared with noninsulin-treated controls, in patients with and without DM. However, with severe hypoglycemia, the increase in mortality was significantly higher in patients without DM (fourfold increase after adjustment), compared with patients with DM (less than threefold increase).
In accordance with previous studies, in our cohort, 9% of the patients hospitalized in medical wards had at least 1 episode of hypoglycemia, mostly moderate hypoglycemia (88%) (1, 2, 4) . Twenty-six percent of patients treated with insulin during hospitalization developed hypoglycemia, including 4% with severe hypoglycemia. Umpierrez et al. (14) reported that 23% of surgical patients with DM who received a basal-bolus insulin regimen developed hypoglycemia. Farrokhi et al. (15) reported that 19% of noncritically ill medical patients with DM developed moderate hypoglycemia during inpatient subcutaneous insulin therapy; 2% of these were documented as having severe hypoglycemia.
In our study, 41% of all hypoglycemic events were associated with insulin, whereas 59% of severe hypoglycemia events were associated with insulin. These rates of noninsulin-related hypoglycemia are in line with previous press.endocrine.org/journal/jcemstudies that reported that about one-half of hypoglycemic events occur in patients with DM or with insulin therapy, but are higher compared with other reports (1, 16-18 ). These differences may result from variable definitions of hypoglycemia or the study population. Many factors may contribute to development of hypoglycemia in the hospital setting, including poor nutrition, renal failure, heart failure, advanced liver disease, advanced age, infections, and the intensity of the treatment regimen (6, (19) (20) (21) . Accordingly, the most common admission diagnoses in the total cohort of patients with hypoglycemia, with and without insulin treatment, were infectious diseases and diseases of the circulatory system.
Most studies have reported that noninsulin-related hypoglycemia is associated with increased mortality compared with insulin-related hypoglycemia (22) (23) (24) (25) . Our results indicate that with a median follow-up of almost 3 years, patients with moderate hypoglycemia during hospitalization had a more than twofold increase in mortality compared with patients without hypoglycemia, and severe hypoglycemia was associated with a threefold increase in mortality. However, in patients with severe hypoglycemia, there was no difference in mortality whether or not the hypoglycemia was insulin related. The increase in in-hospital mortality was much more significant in noninsulin-treated patients with severe hypoglycemia, with a ninefold increase in mortality compared with noninsulin-treated controls (41.2% vs 4.7%). Even a single blood glucose measurement of 40 to 70 mg/dL (2.2 to 3.9 mmol/L) during admission, in noninsulin-treated patients, was associated with a threefold increase in in-hospital mortality risk. There are several possible explanations for the association between hypoglycemia and mortality. First, hypoglycemia may lead directly to death, because low blood glucose levels could potentially trigger fatal arrhythmia, seizures, or stroke. However, this does not account for the increased long-term mortality risk evident in our study. Second, increased mortality rates associated with inpatient hypoglycemia may merely reflect the association between hypoglycemia and more severe illness (1, 2, 22, 25) . Another possibility is that, after a hypoglycemic episode, higher glucose targets are often set due to fear of a recurrent hypoglycemic episode, and this may lead to a higher rate of metabolic complications in the future.
Insulin treatment during admission was associated with increased mortality at the end of follow-up. In patients without DM, mortality rates were 2 times higher in insulin-treated compared with noninsulin-treated patients (59.8% vs 28.5%). Lower risk was evident in patients with DM (44.6% vs 33%). Previous observational and randomized controlled trials have indicated increased mortality risk with inpatient hyperglycemia in both patients with and without DM (26) (27) (28) . Given that the ADA guidelines recommend insulin therapy in hospitalized patients with hyperglycemia, it is possible that the cause of hyperglycemia, leading to insulin therapy, may contribute to the increased mortality risk.
Our study has several limitations. One of the main limitations is the assumption that hypoglycemia in insulintreated patients was insulin associated, although we did not have information about the temporal relation between insulin injection and hypoglycemia. Furthermore, the clinical presentation of hypoglycemia, if at all present, was not recorded in the database. Because there is a considerable variability in definitions of hypoglycemia, our analysis was based on the definition used by the ADA. Another limitation is that data regarding comorbidities was based solely on the medical records, and smoking and alcohol habits were based on self-report. A further limitation is that patients (4) 45 (1) 330 (20) 119 (12) 23 (16) 21 (10) Data are given as number (%).
with a prior history of hyperglycemia or hypoglycemia have a greater chance of having their blood glucose measured more often, with a higher probability of detecting hypoglycemia.
We based the definition of hypoglycemia on either venous blood test or glucometer readings, and in most of the patients, low blood glucose was recorded in both bedside glucometers and venous blood samples. Glucose monitoring during hospitalization is the standard of care for patients with DM, allowing identification of hypoglycemic events. However, given that in patients without DM, the use of bedside glucometers is not as common, and many low blood glucose measurements are identified incidentally in routine blood work, we based our findings on this measurement as well. It should be noted that most patients are treated immediately for hypoglycemia in the event of a low blood glucose reading with a bedside glucometer, and a venous blood sample may be obtained only later and would thus show a normal or even high glucose level.
The major strengths of our study are the large cohort and long-term follow-up, as well as our historical, prospectively collected data that shows the actual treatment of patients admitted to medical wards, as opposed to data from prospective randomized controlled studies in which patients undergo intensive monitoring and treatment adjustments.
In conclusion, our findings suggest that hypoglycemia, whether insulin related or noninsulin related, is associated with increased short-and long-term mortality risk. Mortality risk is higher in insulin-treated patients with moderate hypoglycemia compared with patients without insulin treatment who have similar glucose values. However, with severe hypoglycemia, there was no significant difference between insulin-related and noninsulin-related hypoglycemia.
